Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb 1;82(5):1058–1062. doi: 10.1054/bjoc.1999.1042

Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes

G S Ogg 1, P R Dunbar 1, V Cerundolo 1, A J McMichael 1, N R Lemoine 2, P Savage 3
PMCID: PMC2374430  PMID: 10737389

Abstract

A number of cell surface molecules with specificity to tumour cells have been identified and monoclonal antibodies (mAb) to some of these antigens have been used for targeting tumour cells in vivo. We have sought to link the powerful effector mechanisms of cytotoxic T-cells with the specificity of mAb, by targeting recombinant HLA class I molecules to tumour cells using an antibody delivery system. Soluble recombinant MHC class I/peptide complexes including HLA-A2.1 refolded around an immunodominant peptide from the HIV gag protein (HLA-A2/gag) were synthesized, and the stability of these complexes at 37°C was confirmed by enzyme-linked immunosorbent assay using a conformation-specific antibody. MHC class I-negative lymphoma cells (Daudi) were labelled with a biotinylated mAb specific for a cell surface protein (anti-CD20) then linked to soluble biotinylated HLA-A2/gag complexes using an avidin bridge. Flow cytometry revealed strong labelling of lymphoma cells with HLA-A2/gag complexes (80-fold increase in mean channel fluorescence). CTL specific for HLA-A2/gag efficiently lysed complex-targeted cells, while control CTL (specific for an HLA-A2.1-restricted epitope of melan-A) did not. Similarly, SK-mel-29 melanoma cells were also efficiently lysed by HLA-A2/gag-specific CTL when HLA-A2/gag complexes were linked to their surface via the HMW-MAA specific anti-melanoma antibody 225.28s. With further consideration to the in vivo stability of the MHC class I/peptide complexes, this system could prove a new strategy for the immunological therapy of cancer. © 2000 Cancer Research Campaign

Keywords: cancer, immunotherapy, monoclonal antibody, HLA class I

Full Text

The Full Text of this article is available as a PDF (87.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman J. D., Moss P. A., Goulder P. J., Barouch D. H., McHeyzer-Williams M. G., Bell J. I., McMichael A. J., Davis M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996 Oct 4;274(5284):94–96. doi: 10.1126/science.274.5284.94. [DOI] [PubMed] [Google Scholar]
  2. Berenson R. J., Bensinger W. I., Kalamasz D., Martin P. Elimination of Daudi lymphoblasts from human bone marrow using avidin-biotin immunoadsorption. Blood. 1986 Feb;67(2):509–515. [PubMed] [Google Scholar]
  3. Bodmer W. F., Browning M. J., Krausa P., Rowan A., Bicknell D. C., Bodmer J. G. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann N Y Acad Sci. 1993 Aug 12;690:42–49. doi: 10.1111/j.1749-6632.1993.tb43994.x. [DOI] [PubMed] [Google Scholar]
  4. Buraggi G. L., Callegaro L., Mariani G., Turrin A., Cascinelli N., Attili A., Bombardieri E., Terno G., Plassio G., Dovis M. Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments. Cancer Res. 1985 Jul;45(7):3378–3387. [PubMed] [Google Scholar]
  5. Callan M. F., Tan L., Annels N., Ogg G. S., Wilson J. D., O'Callaghan C. A., Steven N., McMichael A. J., Rickinson A. B. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med. 1998 May 4;187(9):1395–1402. doi: 10.1084/jem.187.9.1395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davies H. S., Pollard S. G., Calne R. Y. Soluble HLA antigens in the circulation of liver graft recipients. Transplantation. 1989 Mar;47(3):524–527. doi: 10.1097/00007890-198903000-00025. [DOI] [PubMed] [Google Scholar]
  7. Dohlsten M., Hedlund G., Akerblom E., Lando P. A., Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9287–9291. doi: 10.1073/pnas.88.20.9287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dohlsten M., Lando P. A., Björk P., Abrahmsén L., Ohlsson L., Lind P., Kalland T. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother. 1995 Sep;41(3):162–168. doi: 10.1007/BF01521342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dohlsten M., Sundstedt A., Björklund M., Hedlund G., Kalland T. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer. 1993 May 28;54(3):482–488. doi: 10.1002/ijc.2910540321. [DOI] [PubMed] [Google Scholar]
  10. Eisenbarth G. S., Haynes B. F., Schroer J. A., Fauci A. S. Production of monoclonal antibodies reacting with peripheral blood mononuclear cell surface differentiation antigens. J Immunol. 1980 Mar;124(3):1237–1244. [PubMed] [Google Scholar]
  11. Elliott T. J., Eisen H. N. Allorecognition of purified major histocompatibility complex glycoproteins by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2728–2732. doi: 10.1073/pnas.85.8.2728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Garboczi D. N., Hung D. T., Wiley D. C. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3429–3433. doi: 10.1073/pnas.89.8.3429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hird V., Maraveyas A., Snook D., Dhokia B., Soutter W. P., Meares C., Stewart J. S., Mason P., Lambert H. E., Epenetos A. A. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993 Aug;68(2):403–406. doi: 10.1038/bjc.1993.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kane K. P., Sherman L. A., Mescher M. F. Molecular interactions required for triggering alloantigen-specific cytolytic T lymphocytes. J Immunol. 1989 Jun 15;142(12):4153–4160. [PubMed] [Google Scholar]
  15. Klein E., Klein G., Nadkarni J. S., Nadkarni J. J., Wigzell H., Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968 Jul;28(7):1300–1310. [PubMed] [Google Scholar]
  16. Knuth A., Wölfel T., Klehmann E., Boon T., Meyer zum Büschenfelde K. H. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2804–2808. doi: 10.1073/pnas.86.8.2804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ledermann J. A., Begent R. H., Massof C., Kelly A. M., Adam T., Bagshawe K. D. A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer. 1991 Mar 12;47(5):659–664. doi: 10.1002/ijc.2910470505. [DOI] [PubMed] [Google Scholar]
  18. Lone Y. C., Motta I., Mottez E., Guilloux Y., Lim A., Demay F., Levraud J. P., Kourilsky P., Abastado J. P. In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes. J Immunother. 1998 Jul;21(4):283–294. doi: 10.1097/00002371-199807000-00006. [DOI] [PubMed] [Google Scholar]
  19. Magnani P., Paganelli G., Modorati G., Zito F., Songini C., Sudati F., Koch P., Maecke H. R., Brancato R., Siccardi A. G. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med. 1996 Jun;37(6):967–971. [PubMed] [Google Scholar]
  20. Maloney D. G., Liles T. M., Czerwinski D. K., Waldichuk C., Rosenberg J., Grillo-Lopez A., Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994 Oct 15;84(8):2457–2466. [PubMed] [Google Scholar]
  21. Moro M., Pelagi M., Fulci G., Paganelli G., Dellabona P., Casorati G., Siccardi A. G., Corti A. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res. 1997 May 15;57(10):1922–1928. [PubMed] [Google Scholar]
  22. Neri D., Natali P. G., Petrul H., Soldani P., Nicotra M. R., Vola R., Rivella A., Creighton A. M., Neri P., Mariani M. Recombinant anti-human melanoma antibodies are versatile molecules. J Invest Dermatol. 1996 Aug;107(2):164–170. doi: 10.1111/1523-1747.ep12329566. [DOI] [PubMed] [Google Scholar]
  23. Ogg G. S., Jin X., Bonhoeffer S., Dunbar P. R., Nowak M. A., Monard S., Segal J. P., Cao Y., Rowland-Jones S. L., Cerundolo V. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998 Mar 27;279(5359):2103–2106. doi: 10.1126/science.279.5359.2103. [DOI] [PubMed] [Google Scholar]
  24. Paganelli G., Magnani P., Zito F., Villa E., Sudati F., Lopalco L., Rossetti C., Malcovati M., Chiolerio F., Seccamani E. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991 Nov 1;51(21):5960–5966. [PubMed] [Google Scholar]
  25. Parham P., Barnstable C. J., Bodmer W. F. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol. 1979 Jul;123(1):342–349. [PubMed] [Google Scholar]
  26. Parker K. C., Bednarek M. A., Hull L. K., Utz U., Cunningham B., Zweerink H. J., Biddison W. E., Coligan J. E. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol. 1992 Dec 1;149(11):3580–3587. [PubMed] [Google Scholar]
  27. Perez P., Hoffman R. W., Shaw S., Bluestone J. A., Segal D. M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985 Jul 25;316(6026):354–356. doi: 10.1038/316354a0. [DOI] [PubMed] [Google Scholar]
  28. Riethmüller G., Holz E., Schlimok G., Schmiegel W., Raab R., Höffken K., Gruber R., Funke I., Pichlmaier H., Hirche H. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998 May;16(5):1788–1794. doi: 10.1200/JCO.1998.16.5.1788. [DOI] [PubMed] [Google Scholar]
  29. Riethmüller G., Johnson J. P. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol. 1992 Oct;4(5):647–655. doi: 10.1016/0952-7915(92)90041-c. [DOI] [PubMed] [Google Scholar]
  30. Romero P., Gervois N., Schneider J., Escobar P., Valmori D., Pannetier C., Steinle A., Wolfel T., Lienard D., Brichard V. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol. 1997 Sep 1;159(5):2366–2374. [PubMed] [Google Scholar]
  31. Schneck J., Maloy W. L., Coligan J. E., Margulies D. H. Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: estimation of the affinity of a T cell receptor for MHC. Cell. 1989 Jan 13;56(1):47–55. doi: 10.1016/0092-8674(89)90982-3. [DOI] [PubMed] [Google Scholar]
  32. Terness P., Dufter C., Otto G., Opelz G. Allograft survival following immunization with membrane-bound or soluble peptide MHC class I donor antigens: factors relevant for the induction of rejection by indirect recognition. Transpl Int. 1996;9(1):2–8. doi: 10.1007/BF00336805. [DOI] [PubMed] [Google Scholar]
  33. Toshitani K., Braud V., Browning M. J., Murray N., McMichael A. J., Bodmer W. F. Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):236–240. doi: 10.1073/pnas.93.1.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Townsend A., Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol. 1989;7:601–624. doi: 10.1146/annurev.iy.07.040189.003125. [DOI] [PubMed] [Google Scholar]
  35. Valone F. H., Kaufman P. A., Guyre P. M., Lewis L. D., Memoli V., Deo Y., Graziano R., Fisher J. L., Meyer L., Mrozek-Orlowski M. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol. 1995 Sep;13(9):2281–2292. doi: 10.1200/JCO.1995.13.9.2281. [DOI] [PubMed] [Google Scholar]
  36. Weiner L. M., Alpaugh R. K., Amoroso A. R., Adams G. P., Ring D. B., Barth M. W. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Cancer Immunol Immunother. 1996 Mar;42(3):141–150. doi: 10.1007/s002620050264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wilson J. L., Cunningham A. C., Kirby J. A. Alloantigen presentation by B cells: analysis of the requirement for B-cell activation. Immunology. 1995 Nov;86(3):325–330. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES